BEIJING (Reuters) – Chinese vaccine specialist CanSino Biologics Inc has obtained patent approval from Beijing for its COVID-19 Ad5-nCOV vaccine candidate, state media reported, citing documents from the intellectual property regulator from the country.
This is the first COVID-19 vaccine patent granted by China, the People’s Daily public newspaper reported on Sunday.
The document cited documents released by China’s State Intellectual Property Administration indicating that the patent was issued on August 11.
Saudi Arabia this month announced plans to begin Phase III clinical trials for the CanSino vaccine. CanSino said it is also in talks with Russia, Brazil and Chile to start Phase III trials in those countries.
CanSino shares in Hong Kong rose about 14% in Monday morning’s session. Its Shanghai shares rose 6.6% as of noon.
Reporting by Sophie Yu and Brenda Goh; Editing by Tom Hogue
Our standards:Thomson Reuters Trust Principles.